Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort

Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort

Abstract Introduction Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (Aβ) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort. Methods Community-dwelling demen...

Full description

Saved in:
Bibliographic Details
Main Authors: Menayit Tamrat Dresse, Pamela C. L. Ferreira, Akshay Prasadan, Jihui L. Diaz, Xuemei Zeng, Bruna Bellaver, Guilherme Povala, Victor L. Villemagne, M. Ilyas Kamboh, Ann D. Cohen, Tharick A. Pascoal, Mary Ganguli, Beth E. Snitz, C. Elizabeth Shaaban, Thomas K. Karikari
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Alzheimer’s Research & Therapy
Subjects:
Amyloid beta
Tau pathology
Neurodegeneration
Neuroimaging
ATN framework
P-tau217
Online Access:https://doi.org/10.1186/s13195-025-01803-w
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (Aβ) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort. Methods Community-dwelling dementia-free (n = 113, including 102 (91%) cognitively normal) participants underwent ATN neuroimaging and plasma biomarker assessments. Results Plasma Aβ42/Aβ40, p-tau181, and p-tau217 showed significant associations with Aβ-PET status, (adjusted odds ratio [AOR] of 1.74*10–24, 1.47, and 3.43*103, respectively (p-values < 0.05), with p-tau217 demonstrating the highest classification accuracy for Aβ-PET status (AUC = 0.94). Plasma p-tau181 and p-tau217 showed significant associations with tau-PET status (AOR: 1.50 and 22.24, respectively (p-values < 0.05), with comparable classification accuracies for tau-PET status (AUC = 0.74 and 0.70, respectively). Only plasma NfL showed significant association with neurodegeneration based on cortical thickness (AOR = 1.09, p-value < 0.05). Conclusion Our findings highlight the potential of plasma p-tau217 as a biomarker for brain Aβ and tau pathophysiology, p-tau181 for tau abnormalities, and NfL for neurodegeneration in the community.
ISSN:1758-9193

Similar Items